This article examines the results of the COMMENCE trial, which evaluated the safety and effectiveness of surgical aortic valve replacement using RESILIA tissue valves during a five-year period in patients with native bicuspid aortic valves, comparing outcomes with those of patients with tricuspid aortic valves.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Aortic Valve
December 12, 2024
December 5, 2024
Development of myocardial fibrosis in patients with aortic stenosis precedes left ventricular decompensation and is associated with an adverse long-term prognosis.
November 26, 2024
Neurohormonal modulation and afterload reduction are essential for treating heart failure with reduced ejection fraction (HFrEF). In HFrEF patients with concomitant moderate aortic stenosis (AS), therapy with transcatheter aortic valve replacement (TAVR) may be complementary to guideline-directed medical therapy (GDMT).
November 26, 2024
This study compared outcomes between patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV TAVR) and redo surgical aortic valve replacement (redo SAVR) using a retrospective analysis of institutional databases, which included data from 2013 to 2022 for TAVR and 2011 to 2022 for SAVR.
November 26, 2024
The EARLY TAVR trial investigators randomly assigned patients with asymptomatic severe aortic stenosis to undergo either early transfemoral transcatheter aortic valve replacement (TAVR) or clinical surveillance. The primary end point was a composite of death, stroke, or unplanned hospitalization for cardiovascular causes.
November 7, 2024
Aortic stenosis is the most prevalent valvular heart condition necessitating surgical intervention, with full sternotomy (FS) traditionally being the standard approach for surgical aortic valve replacement (SAVR).
October 31, 2024
The role of transcatheter aortic valve replacement (TAVR) for the treatment of aortic stenosis in the pre- and post-lung transplant population is limited. This specific patient population is considered high risk for general anesthesia and for surgical aortic valve replacement.
October 31, 2024
This study reports on the seven-year outcomes of an international trial, which evaluated a novel bioprosthetic aortic valve prosthesis aimed at improving tissue durability.
October 24, 2024
There is limited data available from randomized trials comparing outcomes between transcatheter aortic valve replacement (TAVR) and surgery in patients with different risks and follow-up periods of at least four years or longer.
October 17, 2024
The AVATAR Trial addressed the question of when and how to treat asymptomatic patients with severe aortic stenosis (AS) and normal left ventricular (LV) systolic function. In the current report, the authors present the extended follow-up.